Precision BioSciences Raises $7.5M in Funding from TG Therapeutics

Precision BioSciences just reminded the biotech world that sometimes progress shows up as a quiet check with very loud implications. The Durham crew pulled in $7.5M tied to its partnership with TG Therapeutics. Not a flashy venture round. No confetti cannons. Just $5.25M in milestone cash and a $2.25M equity purchase at $11.17 per share tied to the progress of azercabtagene zapreleucel in a Phase 1 study for progressive multiple sclerosis. Translation for the non lab coat crowd. The science is moving forward and the partner is paying attention.

Credit to CEO Michael Amoroso for steering a company that understands the long game of biotech. Precision BioSciences was built on the ARCUS genome editing platform, a technology that sounds like a character in a sci fi novel but behaves more like a molecular surgeon. Small. Precise. Purpose built to edit DNA with intent. That kind of precision is not just branding. It is the business model.

Respect also goes to the architects who started this whole thing. Derek Jantz, Ph.D., Jeff Smith, Ph.D., and Matt Kane laid the scientific groundwork back in 2006. Jeff Smith now continues the mission as CRO Jeff Smith, Ph.D., pushing the platform forward while the company advances programs like PBGENE HBV and PBGENE DMD. Chronic hepatitis B and Duchenne muscular dystrophy are not small targets. They are the kind of diseases where a breakthrough does not just move a stock chart. It changes the trajectory of human lives.

Behind the curtain there is a leadership bench that knows how to translate deep science into real clinical momentum. CSO Cassie Gorsuch, Chief Development and Business Officer Cindy Atwell, CFO Alex Kelly, and SVP, Head of Clinical Development Murray Abramson are part of the engine room making sure the platform actually becomes medicine.

The azer cel program with TG Therapeutics is another smart move in the Precision playbook. Partnerships like this do 2 things. They validate the underlying science and they create non dilutive capital while the company advances its internal pipeline. Precision keeps focus on its in vivo ARCUS therapies while still collecting economic upside as partners move programs forward. That is not luck. That is strategic patience.

Genome editing is one of those arenas where hype tends to run faster than results. Precision BioSciences seems comfortable doing the opposite. Move the science. Hit the milestones. Collect the receipts. Repeat.